File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization

TitleThe outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization
Authors
KeywordsElderly
Hepatitis
Hepatocellular carcinoma
Transarterial chemoembolization
Issue Date2009
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2009, v. 115 n. 23, p. 5507-5515 How to Cite?
AbstractBACKGROUND: The authors evaluated and compared the treatment outcomes of transarterial chemoembolization (TACE) between young (≤70 years) and elderly (>70 years) patients at their institute over an 18-year period. METHODS: Advanced hepatocellular carcinoma (HCC) patients who received TACE at the authors' center were analyzed retrospectively. The demographic data, TACE-related morbidities, and survival outcome were compared between these 2 age groups. RESULTS: Between 1989 and 2006, 843 patients who were ≤70 years old and 197 patients who were >70 years old received TACE treatment for advanced HCC. There were significantly more comorbid illnesses associated with the elderly patients than the young patients (64 % vs 33%, P < .01). Moreover, elderly patients who received TACE treatment for HCC were at earlier stages of disease (P < .01). Both the overall median survival (14.0 months vs 8.1 months, P < .003) and disease-specific survival (15.2 months vs 8.7 months, P < .001) were significantly higher in elderly than young patients. The most commonly encountered TACE-related morbidity in both age groups was liver function derangement. Young patients had a significantly higher rate of developing liver derangement after TACE than elderly patients (21% vs 11%, P < .01). Conversely, the elderly patients had a significantly higher rate of developing peptic ulcer disease with TACE treatment than young patients (2.5% vs 0.5%, P=.01). Overall, there was no significant difference in TACE-related mortality between the young and elderly patients (3% vs 4%, P=.49). CONCLUSIONS: This study has confirmed the comparable efficacy and tolerability in using TACE for the treatment of advanced HCC in young and elderly patient populations. © 2009 American Cancer Society.
Persistent Identifierhttp://hdl.handle.net/10722/87630
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorYao, TJen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorEpstein, RJen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T09:32:18Z-
dc.date.available2010-09-06T09:32:18Z-
dc.date.issued2009en_HK
dc.identifier.citationCancer, 2009, v. 115 n. 23, p. 5507-5515en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87630-
dc.description.abstractBACKGROUND: The authors evaluated and compared the treatment outcomes of transarterial chemoembolization (TACE) between young (≤70 years) and elderly (>70 years) patients at their institute over an 18-year period. METHODS: Advanced hepatocellular carcinoma (HCC) patients who received TACE at the authors' center were analyzed retrospectively. The demographic data, TACE-related morbidities, and survival outcome were compared between these 2 age groups. RESULTS: Between 1989 and 2006, 843 patients who were ≤70 years old and 197 patients who were >70 years old received TACE treatment for advanced HCC. There were significantly more comorbid illnesses associated with the elderly patients than the young patients (64 % vs 33%, P < .01). Moreover, elderly patients who received TACE treatment for HCC were at earlier stages of disease (P < .01). Both the overall median survival (14.0 months vs 8.1 months, P < .003) and disease-specific survival (15.2 months vs 8.7 months, P < .001) were significantly higher in elderly than young patients. The most commonly encountered TACE-related morbidity in both age groups was liver function derangement. Young patients had a significantly higher rate of developing liver derangement after TACE than elderly patients (21% vs 11%, P < .01). Conversely, the elderly patients had a significantly higher rate of developing peptic ulcer disease with TACE treatment than young patients (2.5% vs 0.5%, P=.01). Overall, there was no significant difference in TACE-related mortality between the young and elderly patients (3% vs 4%, P=.49). CONCLUSIONS: This study has confirmed the comparable efficacy and tolerability in using TACE for the treatment of advanced HCC in young and elderly patient populations. © 2009 American Cancer Society.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.subjectElderlyen_HK
dc.subjectHepatitisen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectTransarterial chemoembolizationen_HK
dc.subject.meshCarcinoma, Hepatocellular - mortality - therapy-
dc.subject.meshChemoembolization, Therapeutic - adverse effects - mortality-
dc.subject.meshInfusions, Intra-Arterial-
dc.subject.meshLiver Neoplasms - mortality - therapy-
dc.subject.meshSurvival Analysis-
dc.titleThe outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolizationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0008-543X&volume=115&issue=23&spage=5507&epage=5515&date=2009&atitle=The+outcomes+of+elderly+patients+with+hepatocellular+carcinoma+treated+with+transarterial+chemoembolizationen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailYao, TJ: tjyao@hkucc.hku.hken_HK
dc.identifier.emailEpstein, RJ: repstein@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityYao, TJ=rp00284en_HK
dc.identifier.authorityEpstein, RJ=rp00501en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/cncr.24636en_HK
dc.identifier.pmid19701904-
dc.identifier.scopuseid_2-s2.0-72249100065en_HK
dc.identifier.hkuros168444en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-72249100065&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume115en_HK
dc.identifier.issue23en_HK
dc.identifier.spage5507en_HK
dc.identifier.epage5515en_HK
dc.identifier.isiWOS:000271918600020-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridYao, TJ=7401886444en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridEpstein, RJ=34975074500en_HK
dc.identifier.scopusauthoridNg, KK=35248894000en_HK
dc.identifier.scopusauthoridChok, SH=6602753231en_HK
dc.identifier.scopusauthoridCheung, TT=36847499900en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats